expected survival less than 3 days treatment with immunosuppressive drugs (tocilizumab, sarilumab) with corticosteroids being allowed neoplastic disease either active or without complete remission immunosuppressed patients (except treatment with corticosteroids for respiratory distress) pregnant or lactating women participation in another clinical trial with an experimental drug in the last 30 days other pathologies that, in medical judgment, contraindicate participation in the study

expected survival less than 3 days treatment with immunosuppressive drugs (tocilizumab, sarilumab) with corticosteroids being allowed neoplastic disease either active or without complete remission immunosuppressed patients (except treatment with corticosteroids for respiratory distress) pregnant or lactating women participation in another clinical trial with an experimental drug in the last 30 days other pathologies that, in medical judgment, contraindicate participation in the study

1. expected survival less than 3 days 2. treatment with immunosuppressive drugs (tocilizumab, sarilumab) with corticosteroids being allowed 3. neoplastic disease either active or without complete remission 4. immunosuppressed patients (except treatment with corticosteroids for respiratory distress) 5. pregnant or lactating women 6. participation in another clinical trial with an experimental drug in the last 30 days 7. other pathologies that, in medical judgment, contraindicate participation in the study

1. expected survival less than 3 days 2. treatment with immunosuppressive drugs (tocilizumab, sarilumab) with corticosteroids being allowed 3. neoplastic disease either active or without complete remission 4. immunosuppressed patients (except treatment with corticosteroids for respiratory distress) 5. pregnant or lactating women 6. participation in another clinical trial with an experimental drug in the last 30 days 7. other pathologies that, in medical judgment, contraindicate participation in the study